Maternal Thyroid Dysfunction, Intrauterine and Fetal Growth Restriction- Juniper Publishers
JUNIPER PUBLISHERS- OPEN ACCESS JOURNAL OF REVIEWS & RESEARCH
Maternal Thyroid Dysfunction, Intrauterine and Fetal Growth Restriction
Authored by Ahmed RG
Letter to Editor
The bioavailability of maternal thyroid hormones
(THs) during pregnancy is critical for the development and growth of
fetus and neonates [1-58].
During the second half of gestation, thyroxine (T4) and 3, 5,
3'-triiodothyronine (T3) induce intrauterine growth through increase the
fetal anabolic state/ metabolic state and the positive action on the
growth regulatory factors and other endocrine systems [59-60].
In late gestation period, the prepartum elevation in the
bioavailability of T3 can mediate the maturational actions of the
glucocorticoids and increase the functionality of the sympathetic
nervous system [60-62]. In turn, this mediation can protect the neonate from the stress of delivery and from the new extrauterine environment [60].
On the other hand, intrauterine growth restriction or
fetal growth restriction, a heterogeneous syndrome, means a fetus that
cannot reach its growth potential [63-65].
These defects, impair fetal growth and compromises the neonatal
adaptation to extrauterine life, can be attributed to the deficiency of
THs during intrauterine development [66-68].
These data are reinforced by the results of fetal growth restriction in
human and experimental animals (undernutrition and placental
insufficiency) [69-72]. Also, hypothyroidism in sheep, goats, horses, and pigs induces the fetal growth restriction [60,73,74].
In epidemiological studies, the presence of anti thyroid antibodies
(ATA) can increase the risk of intrauterine growth restriction or small
for gestational age (SGA; infants are smaller in size and weight than
normal) [65,75,76].
More interestingly, the risks of birth hypoxia, perinatal death,
neonatal obstacles, neurodevelopmental and metabolic syndromes during
adult life such as hypertension, type 2 diabetes, and coronary heart
disease were increased during intrauterine and fetal growth restriction [77-81].
Indeed, intrauterine growth restriction is related to the gestational
hypertensive disorders, under nutrition, infection, smoking, and
unexplained factors [82]. Sharma [83] reported that intrauterine growth restriction is a main and silent cause of fetal and neonatal morbidity and mortality.
Conclusion
In conclusion, it is also worth stating that THs
promote the general body growth and the development of fetal individual
tissues and organs. In addition, any disorders in the levels of THs
during intrauterine development may cause intrauterine and fetal growth
restriction. These disorders may disrupt the development and growth of
fetus and neonates, and cause several lifelong consequences through
permanent fluctuations in most biological systems. Thus, monitoring the
activity of maternal THs may prevent any undesirable pathological state
during intrauterine development. Additional studies should evaluate the
relation between the maternal thyroid disorders, thyroid auto
antibodies, intrauterine and fetal growth restriction [84-89].
Conflict of Interest
The author declares that no competing financial interests exist.
For more
Open Access Journals in Juniper
Publishers please click on: https://juniperpublishers.com
For more
articles in Open Access
Journal of Reviews & Research please click on:
https://juniperpublishers.com/arr/index.php
https://juniperpublishers.com/arr/index.php
To know
more about Peer Review Journal
of Reviews & Research click on:
Comments
Post a Comment